Quantbot Technologies LP Decreases Stock Holdings in Nuvation Bio Inc. (NYSE:NUVB)

Quantbot Technologies LP lessened its stake in Nuvation Bio Inc. (NYSE:NUVB) by 56.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 31,345 shares of the company’s stock after selling 40,881 shares during the period. Quantbot Technologies LP’s holdings in Nuvation Bio were worth $83,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in NUVB. Frazier Life Sciences Management L.P. purchased a new stake in Nuvation Bio in the third quarter valued at about $2,790,000. Wexford Capital LP raised its position in shares of Nuvation Bio by 930.2% in the 3rd quarter. Wexford Capital LP now owns 651,767 shares of the company’s stock valued at $1,493,000 after purchasing an additional 588,500 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Nuvation Bio by 39.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,945,983 shares of the company’s stock worth $5,176,000 after purchasing an additional 551,968 shares in the last quarter. FMR LLC grew its position in Nuvation Bio by 1.4% during the 3rd quarter. FMR LLC now owns 29,238,871 shares of the company’s stock worth $66,957,000 after purchasing an additional 416,932 shares during the last quarter. Finally, Peapod Lane Capital LLC acquired a new position in Nuvation Bio during the 4th quarter valued at approximately $1,042,000. 61.67% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on NUVB. HC Wainwright reduced their target price on Nuvation Bio from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Monday, March 10th. Jones Trading initiated coverage on Nuvation Bio in a report on Wednesday, March 12th. They set a “buy” rating and a $10.00 target price for the company. Wedbush reiterated an “outperform” rating and issued a $5.00 price target on shares of Nuvation Bio in a report on Thursday, March 27th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $10.00 price objective (up from $6.00) on shares of Nuvation Bio in a research note on Tuesday, January 7th.

Nuvation Bio Stock Down 2.5 %

NYSE:NUVB opened at $1.78 on Tuesday. Nuvation Bio Inc. has a 52 week low of $1.70 and a 52 week high of $3.97. The stock’s 50-day moving average price is $2.17 and its 200-day moving average price is $2.47. The stock has a market capitalization of $601.16 million, a PE ratio of -0.82 and a beta of 1.47.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.